Brands & Intellectual Property
Maximising brand power forms the heart of commercial strategy for businesses in nearly every industry, whether major names or start-ups with big ambitions.
There have never been so many opportunities to seize, or threats to avoid, whether that’s protecting your brand from unauthorised use by your competitors, developing online content deals, negotiating TV format rights, or clamping down on counterfeiting or cybersquatting activities.
We help clients ensure that their brand is actively managed and defended, from the inception of an idea through value analysis, global IP protection and exploitation, concept roll-out, commercialisation, dealing with disputes and beyond.
Consistently ranked as a top-tier law firm for our brands and IP work, we have a long track-record helping some of the world’s biggest blue chips and SMEs build up their brand presence in their marketplace and make best use of their IP assets.
Our clients value the strength of our large, specialist team, as well as the depth of our sector insight in areas such as advertising & marketing, media & entertainment, retail, technology, sports, manufacturing and professional services.
Code red! (How to deal with a media crisis)09 November 2017
Every brand’s nightmare. It’s 5 o’clock on a Friday and the phone rings….a tabloid newspaper has an exposé and they want your comment for their article on Sunday.
Socially embarrassing12 October 2017
This session will focus on what makes a good social media strategy and how brands can get it wrong.
UPC – UK moves forward whilst Germany stalls13 July 2017
The Unified Patent Court (UPC) is intended to provide a regional forum resolve patent disputes. UPC decisions will have effect in all 25 states participating in the UPC, providing a single forum to resolve disputes.
Squeezed out of validity and into the jurisdiction13 July 2017
UCB licensed Chugai rights to its tocilizumab patents. The licence contained an exclusive jurisdiction clause in favour of the English courts. Only one US patent remained in force. Chugai wanted a declaration that its tocilizumab products (sold only in the US) fell outside of the scope of the last patent and accordingly no royalty payments were due under the licence.
Sandoz & Hexal v Searle & Janssen Sciences Ireland: What is the formula for patent extensions?13 July 2017
The UK High Court has held that a pharmaceutical product claimed only within a Markush formula and not expressly referred to in the patent was protected by the patent for the purposes of obtaining a Supplementary Protection Certificate (SPC).
Watching out for individual character: Nike design for electronic wristband validly registered13 July 2017
The EU General Court has dismissed an action to invalidate a Registered Community Design held by Nike for electronic wristbands. The case serves as a useful reminder of the principles to be applied in assessing whether a design has sufficient individual character to be registered.
It’s not just about Getting(G) Data(D) Protection(P) Ready(R): some digital businesses and infrastructure providers shouldn’t forget to be ‘NIS’11 July 2017
May 2018 is a month which will already be highlighted in the calendars of those responsible for their organisations’ compliance with the General Data Protection Regulation (GDPR). It’s now under a year away. But for some digital businesses and infrastructure providers, when it comes to security risk management and reporting obligations, the GDPR isn’t the whole story.